English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/53552
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Title

The disease-protective complement factor H allotypic variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activity

AuthorsTortajada, Agustín ; Montes, Tamara ; Martínez-Barricarte, Rubén ; Morgan, B. Paul; Harris, Claire L.
Issue Date15-Sep-2009
PublisherOxford University Press
CitationHuman Molecular Genetics 18(18):3452-61(2009)
AbstractMutations and polymorphisms in the gene encoding factor H (CFH) have been associated with atypical haemolytic uraemic syndrome, dense deposit disease and age-related macular degeneration. The disease-predisposing CFH variants show a differential association with pathology that has been very useful to unravel critical events in the pathogenesis of one or other disease. In contrast, the factor H (fH)-Ile62 polymorphism confers strong protection to all three diseases. Using ELISA-based methods and surface plasmon resonance analyses, we show here that the protective fH-Ile62 variant binds more efficiently to C3b than fH-Val62 and competes better with factor B in proconvertase formation. Functional analyses demonstrate an increased cofactor activity for fH-Ile62 in the factor I-mediated cleavage of fluid phase and surface-bound C3b; however, the two fH variants show no differences in decay accelerating activity. From these data, we conclude that the protective effect of the fH-Ile62 variant is due to its better capacity to bind C3b, inhibit proconvertase formation and catalyze inactivation of fluid-phase and surface-bound C3b. This demonstration of the functional consequences of the fH-Ile62 polymorphism provides relevant insights into the complement regulatory activities of fH that will be useful in disease prediction and future development of effective therapeutics for disorders caused by complement dysregulation
Description38 p.- 7 fig.
Publisher version (URL)http://dx.doi.org/10.1093/hmg/ddp289
URIhttp://hdl.handle.net/10261/53552
DOI10.1093/hmg/ddp289
ISSN0964-6906
E-ISSN1460-2083
Appears in Collections:(CIB) Artículos
Files in This Item:
File Description SizeFormat 
2009_Tortajada et al_Hum Mol Genet.pdf652,36 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.